Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine

ChAdOx1 nCoV-19/AZD1222 疫苗表达的类似天然的 SARS-CoV-2 刺突糖蛋白

阅读:4
作者:Yasunori Watanabe, Luiza Mendonça, Elizabeth R Allen, Andrew Howe, Mercede Lee, Joel D Allen, Himanshi Chawla, David Pulido, Francesca Donnellan, Hannah Davies, Marta Ulaszewska, Sandra Belij-Rammerstorfer, Susan Morris, Anna-Sophia Krebs, Wanwisa Dejnirattisai, Juthathip Mongkolsapaya, Piyada Supas

Abstract

Vaccine development against the SARS-CoV-2 virus focuses on the principal target of the neutralizing immune response, the spike (S) glycoprotein. Adenovirus-vectored vaccines offer an effective platform for the delivery of viral antigen, but it is important for the generation of neutralizing antibodies that they produce appropriately processed and assembled viral antigen that mimics that observed on the SARS-CoV-2 virus. Here, we describe the structure, conformation and glycosylation of the S protein derived from the adenovirus-vectored ChAdOx1 nCoV-19/AZD1222 vaccine. We demonstrate native-like post-translational processing and assembly, and reveal the expression of S proteins on the surface of cells adopting the trimeric prefusion conformation. The data presented here confirms the use of ChAdOx1 adenovirus vectors as a leading platform technology for SARS-CoV-2 vaccines.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。